TAURIGA SCIENCES INC - TAUG STOCK NEWS

Tauriga Sciences (OTCQB: TAUG) has entered a Strategic Alliance with Psychedelic Water to enhance brand awareness and sales while expanding distribution networks for both companies. Psychedelic Water features a unique blend of kava root, damiana leaf, and green tea extract. The partnership aims to increase market presence both domestically and internationally, with initial collaboration starting at the MJBizCon Tradeshow in Las Vegas from October 19-22, 2021, where both companies will exhibit together.

Tauriga Sciences, Inc. (TAUG) announced its development of a proprietary Ashwagandha extract-infused chewing gum. Each piece will contain 88mg of high-quality Ashwagandha. The product aims to incorporate the company's expertise in creating innovative chewing gums, maintaining high safety and quality standards. The selected flavor for the gum is Asian Water Mint. The company, active in the life sciences sector, also produces various CBD and CBG-infused products under its Tauri-Gum™ brand, catering to diverse customer needs.

Tauriga Sciences, Inc. (OTCQB: TAUG) has launched a significant advertising campaign for its flagship product, Tauri-Gum™, in Times Square, New York City. Scheduled from October 15, 2021, to January 5, 2022, the campaign will feature a large digital billboard at The Gateway to New York, ensuring high visibility during major events like New Year’s Eve. The campaign will showcase Tauri-Gum™ with ads airing five times an hour, totaling over 8,300 spots. The initiative aims to boost Tauri-Gum™ exposure and enhance the company’s e-commerce efforts, featuring a promo code for potential discounts.

Tauriga Sciences, Inc. (OTCQB: TAUG) has expanded its Delta 8 THC infused Gummies line by introducing a new Kiwi & Lemonade flavor, complementing the existing Watermelon Grape variant. Sales for the initial product have been strong and are accelerating.

The company reports ongoing growth in its retail business, with interest from national retailers and plans to announce a significant partnership soon. Tauriga continues to focus on its E-Commerce strategy and various product lines, including CBD and CBG infused products.

Tauriga Sciences, Inc. (OTCQB: TAUG) has initiated the development of a proprietary Kratom extract-infused supplement chewing gum, incorporating 20mg of high-quality Kratom extract per piece. The product is currently in the prototype phase, with a proposed flavor of Granny Smith Green Apple. The Company aims to address a market niche by emphasizing safety, quality assurance, and rigorous testing protocols. As a diversified life sciences company, Tauriga also continues its focus on its existing product lines in the CBD and CBG markets, alongside ongoing pharmaceutical developments.

Tauriga Sciences, Inc. (OTCQB: TAUG) has announced its International Patent Application for a cannabinoid-based chewing gum product was published by the Patent Cooperation Treaty on September 23, 2021. This product aims to treat nausea resulting from chemotherapy. The patent, titled 'Medicated Cannabinoid Compositions, Methods of Manufacturing, and Methods of Treatment,' was filed on March 17, 2021. The company continues its efforts in the pharmaceutical sector while also distributing CBD and CBG infused products through its brand, Tauri-Gum™, which features various flavors.

Tauriga Sciences, Inc. (OTCQB: TAUG) has announced an upgrade to its Exhibitor Booth for the MJBIZCon Tradeshow, scheduled for October 19-22, 2021, in Las Vegas. The booth, now a Corner Booth (# C3057) measuring 10ft by 20ft, reflects significant interest in the company’s products, particularly its Tauri-Gum™ line, which includes various CBD and CBG infused flavors. Tauriga focuses on both retail sales and pharmaceutical development, including a proposed CBD gum for chemotherapy patients, supported by a recently converted patent application.

Tauriga Sciences, Inc. (OTCQB: TAUG) reported record quarterly revenue exceeding $125,000 for the second fiscal quarter of 2022, marking a significant milestone. The company capitalized on its diversified revenue streams, including E-Commerce, retail, tradeshow, and subscription sales, with E-Commerce contributing 65% of total revenue. Additionally, Tauriga continues to advance its pharmaceutical development initiatives. The company is actively participating in key trade shows to expand its market presence.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced that its Tauri-Gum™ and Tauri-Pet™ products are now available on Amazon Prime. This significant move allows Tauriga to reach over 200 million Prime subscribers. The company's revenue continues to grow alongside new customer acquisitions, affirming its strong market presence. Additionally, Tauriga focuses on developing pharmaceutical-grade versions of its products, including a formulation for chemotherapy-related nausea, with a patent application pending for its CBD compositions.